Armin Leitner

Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia

Rüdiger Hehlmann, Michael Lauseker, Susanne Jung-Munkwitz et al. · Journal of Clinical Oncology · 2011 · 323 citations · Full text

Pharmacy, Hematology, Pharmacotherapy +12

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

Alice Fabarius, Armin Leitner, Andreas Hochhaus et al. · Blood · 2011 · 290 citations

Life Sciences, Genetics, Hematology +16

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

Michael Lauseker, Aloïs Gratwohl, Dietrich W. Beelen et al. · Blood · 2009 · 220 citations · Full text

Medicine, Hematology, Oncology +14

A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer

Frank Willeke, Karoline Horisberger, Uta Kraus-Tiefenbacher et al. · British Journal of Cancer · 2007 · 104 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

Benjamin Hanfstein, Martin C. Müller, Sebastian Kreil et al. · Haematologica · 2010 · 52 citations · Full text

Medicine, Hematology, Oncology +16